Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Get Free Report) have earned an average rating of "Moderate Buy" from the twelve research firms that are covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and nine have given a buy rating to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $52.83.
A number of analysts have recently issued reports on EWTX shares. Wedbush reduced their price target on shares of Edgewise Therapeutics from $53.00 to $51.00 and set an "outperform" rating for the company in a research report on Thursday, November 5th. JPMorgan Chase & Co. boosted their price objective on shares of Edgewise Therapeutics from $53.00 to $60.00 and gave the company an "overweight" rating in a research report on Thursday, August 20th. HC Wainwright reaffirmed a "buy" rating on shares of Edgewise Therapeutics in a research report on Wednesday, October 14th. Evercore reiterated an "outperform" rating and issued a $55.00 price objective on shares of Edgewise Therapeutics in a research note on Monday, July 20th. Finally, The Goldman Sachs Group increased their target price on shares of Edgewise Therapeutics from $32.00 to $36.00 and gave the stock a "neutral" rating in a research report on Tuesday, August 11th.
View Our Latest Stock Report on EWTX
Insider Activity at Edgewise Therapeutics
In other news, CFO Michael Nofi sold 4,442 shares of the company's stock in a transaction on Tuesday, November 10th. The shares were sold at an average price of $45.43, for a total value of $201,800.06. Following the transaction, the chief financial officer directly owned 6,495 shares of the company's stock, valued at approximately $295,067.85. This represents a 40.61% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 21.30% of the stock is currently owned by corporate insiders.
Institutional Trading of Edgewise Therapeutics
Institutional investors have recently bought and sold shares of the company. BlackRock Inc. acquired a new position in Edgewise Therapeutics in the 2nd quarter worth about $268,415,000. Jupiter Topco LLC acquired a new stake in shares of Edgewise Therapeutics during the 2nd quarter valued at about $246,945,000. Janus Henderson Group PLC grew its stake in shares of Edgewise Therapeutics by 29.5% in the 1st quarter. Janus Henderson Group PLC now owns 5,915,556 shares of the company's stock valued at $186,289,000 after buying an additional 1,348,706 shares in the last quarter. Bank of America Corp DE bought a new stake in shares of Edgewise Therapeutics in the 2nd quarter valued at approximately $63,312,000. Finally, Marshall Wace LLP grew its stake in shares of Edgewise Therapeutics by 20,477.5% in the 3rd quarter. Marshall Wace LLP now owns 1,255,226 shares of the company's stock valued at $50,962,000 after buying an additional 1,249,126 shares in the last quarter.
Edgewise Therapeutics Trading Down 4.9%
NASDAQ:EWTX opened at $43.68 on Tuesday. The business's fifty day moving average price is $41.34 and its 200 day moving average price is $37.06. The firm has a market capitalization of $4.78 billion, a price-to-earnings ratio of 5.33 and a beta of 0.39. Edgewise Therapeutics has a 1-year low of $19.76 and a 1-year high of $48.78.
Edgewise Therapeutics (NASDAQ:EWTX - Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The company reported $9.65 EPS for the quarter, topping analysts' consensus estimates of ($0.53) by $10.18. Equities analysts forecast that Edgewise Therapeutics will post 9.11 earnings per share for the current year.
About Edgewise Therapeutics
(
Get Free Report)
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for serious muscle disorders. Founded in 2017 and based in Boulder, Colorado, the company researches small-molecule treatments designed to address the underlying biology of muscle and cardiac conditions. Its programs include sevasemten, an investigational therapy for Duchenne and Becker muscular dystrophies, and EDG-7500, an investigational treatment being developed for hypertrophic cardiomyopathy.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Edgewise Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Edgewise Therapeutics wasn't on the list.
While Edgewise Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.